Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
F8 encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. De plus, nous expédions Factor VIII Anticorps (324) et Factor VIII Protéines (24) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 63 products:
Human Factor VIII Kit ELISA pour Sandwich ELISA - ABIN456987
Wang, Yuan, Zhong, Wen, Deng, Liang, Zheng: The anticoagulant effect of PGI2S and tPA in transgenic umbilical vein endothelial cells is linked to up-regulation of PKA and PKC. dans International journal of molecular sciences 2014
Show all 2 Pubmed References
gene is flanked by factor VII (Montrer TH Kits ELISA) and factor X genes; gene encodes a protein homologous to factor VII (Montrer TH Kits ELISA), but lacks critical residues for factor VII (Montrer TH Kits ELISA) activity; functions as an inhibitor of blood coagulation in biochemical assays using zebrafish or human plasmas
CD32 blockade suppresses the FVIII-specific recall response by two ways: i) increasing apoptosis of FVIII-specific memory B-cells and ii) disturbing FVIII-specific T cell response by modulating presentation of rhFVIII to CD4(+) T cells.
Type 2N von Willebrand disease variants were associated with decreased VWF (Montrer VWF Kits ELISA) secretion and impaired factor VIII binding/stability.
Cytokine release was quantified from FVIII(-/-) splenocytes restimulated with FVIII in the absence or presence of different anti-FcgammaRIIB (CD32) Antibodies (anti-CD32 mAbs) over 6 days.
results revealed localized vascular expression of FVIII and von Willebrand factor (Montrer VWF Kits ELISA) and identified lymphatic endothelial cell as a major cellular source of FVIII in extrahepatic tissues.
the results indicate that residues in the C1 and/or C2 domains of factor VIII are implicated in immunogenic factor VIII uptake, at least in vitro Conversely, in vivo, the binding to endogenous von Willebrand factor (Montrer VWF Kits ELISA) masks the reducing effect of mutations in the C domains on factor VIII immunogenicity.
data demonstrate that infusion of platelets containing FVIII triggers neither primary nor memory anti-FVIII immune response in FVIII(null) mice
Both platelet-VWF (Montrer VWF Kits ELISA) and plasma-VWF (Montrer VWF Kits ELISA) are required for optimal platelet-derived FVIII gene therapy for hemophilia A in the presence of inhibitors.
These data support the investigation of FVIII orthologs as treatment modalities in both the congenital and acquired FVIII inhibitor settings.
Activatable bioengineered FIX molecules with FVIII-independent activity might be a promising tool for improving hemophilia A treatment, especially for patients with inhibitors.
This study demonstrated that FVIIIa interacts with Low-density lipoprotein receptor-related protein 1 (Montrer LRP1 Kits ELISA) cluster III.
The aim of this study was to determine the F8 mutations in severe HA (sHA) patients and female carriers
Human FVIII gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD4 (Montrer CD4 Kits ELISA)(+) T cell mediated.
High dose of rhFVIII induces apoptosis in FVIII-specific memory B-cells but does not influence FVIII-specific T cell response.
Case Report: complex recombination with deletion in the F8 and duplication in the TMLHE (Montrer TMLHE Kits ELISA) mediated by int22h copies during early embryogenesis in proband's mother.
Report a diagnostic algorithm that can reliably identify pathogenic variants of factor 8/9 and von Willebrand factor (Montrer VWF Kits ELISA) and diagnose patients with hemophilia A, hemophilia B or von Willebrand disease.
Each hFVIII vector was administered to FVIII knockout (KO) mice at a dose of 10(10) genome copies (GC) per mouse. Criteria for distinguishing the performance of the different enhancer/promoter combinations were established prior to the initiation of the studies.
Relevance of ethnic differences in factor XIII (Montrer UGDH Kits ELISA) activity on laboratory reference ranges.
analysis of co-existing variants in both F8 and PTGS-1 (Montrer PTGS1 Kits ELISA) genes in a three-generation pedigree of hemophilia A
FVIII endocytosis is driven by interaction with LRP1 (Montrer LRP1 Kits ELISA)
A coagulation initiating pathway is revealed in which the TF-FVIIa-nascent FXa (Montrer F10 Kits ELISA) complex activates FVIII apart from thrombin (Montrer F2 Kits ELISA) feedback.
It was concluded that VEGF (Montrer VEGFA Kits ELISA) and factor VIII are important growth factors associated with fetal development in pigs and are identified in all uterine segments.
thrombin (Montrer F2 Kits ELISA) stimulates transglutaminase activity in articular cartilage by directly cleaving factor XIII (Montrer UGDH Kits ELISA) and by receptor-mediated up-regulation of factor XIII (Montrer UGDH Kits ELISA) synthesis
cupredoxin-like A1 subdomains in fVIII contain inter-species differences that are a result of selective pressure on the dissociation rate constant
Factor VIIIc is responsible for tissue invasion during tumor progression.
This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation\; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder.
, procoagulant component
, antihemophilic factor
, coagulation factor VIII
, coagulation factor VIIIc
, factor VIII F8B
, coagulation factor VIII, procoagulant component (hemophilia A)
, factor VIII
, coagulation co-factor